Table 3.

Adverse events and mortality for all patients

	Warfarin patients (n = 99)	Control group (n = 99)	P-value
Myocardial infarction, n (%)	1 (1.0)	0	1.0
Stroke, n (%)	0	1 (1.0)	1.0
Pulmonary embolism, n (%)	0	0
Deep venous thrombosis, n (%)	0	0
Sepsis, n (%)	0	1 (1.0)	1.0
Pneumonia, n (%)	6 (6.1)	10 (10)	0.4
Urinary tract infection, n (%)	14 (14)	14 (14)	1.0
Pressure ulcer, n (%)	10 (10)	10 (10)	1.0
Any adverse event, n (%)	27 (27)	31 (31)	0.6
In-house mortality, n (%)	5 (5.1)	2 (2.0)	0.4
30-day mortality, n (%)	9 (9.1)	7 (7.1)	0.8
1-year mortality, n (%)	26 (26)	26 (26)	1.0